{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T01:53:19Z","timestamp":1770688399090,"version":"3.49.0"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1097\/jcp.0b013e31822cfff2","type":"journal-article","created":{"date-parts":[[2011,10,4]],"date-time":"2011-10-04T19:58:34Z","timestamp":1317758314000},"page":"555-562","source":"Crossref","is-referenced-by-count":34,"title":["DRD2 Taq1A Polymorphism Modulates Prolactin Secretion Induced by Atypical Antipsychotics in Healthy Volunteers"],"prefix":"10.1097","volume":"31","author":[{"given":"Rosario","family":"L\u00f3pez-Rodr\u00edguez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Rom\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jes\u00fas","family":"Novalbos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Laura","family":"Pelegrina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dolores","family":"Ochoa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Abad-Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-2-20210128","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1592\/phco.29.1.64","article-title":"Antipsychotic-induced hyperprolactinemia.","volume":"29","author":"Bostwick","year":"2009","journal-title":"Pharmacotherapy"},{"key":"R2-2-20210128","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/sj.mp.4002009","article-title":"Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research.","volume":"12","author":"Arranz","year":"2007","journal-title":"Mol Psychiatry"},{"key":"R3-2-20210128","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/JCP.0b013e31802e68d5","article-title":"Lahuis, BE, Hermans, MH, et al. Prolactin release in children treated with risperidone: impact and role of CYP2D6 metabolism.","volume":"27","author":"Troost","year":"2007","journal-title":"J Clin Psychopharmacol"},{"key":"R4-2-20210128","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1097\/00008571-199712000-00006","article-title":"D2 dopamine receptor gene (DRD2) Taq1 A polymorphism: reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele.","volume":"7","author":"Thompson","year":"1997","journal-title":"Pharmacogenetics"},{"key":"R5-2-20210128","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1001\/archpsyc.1991.01810310066012","article-title":"Allelic association of the D2 dopamine receptor gene with receptor-binding characteristics in alcoholism.","volume":"48","author":"Noble","year":"1991","journal-title":"Arch Gen Psychiatry"},{"key":"R6-2-20210128","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/S0006-3223(96)00543-4","article-title":"Association of TaqI A polymorphism of dopamine D2 receptor gene and tardive dyskinesia in schizophrenia.","volume":"41","author":"Chen","year":"1997","journal-title":"Biol Psychiatry"},{"key":"R7-2-20210128","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s00228-006-0234-8","article-title":"Antipsychotic-induced extrapyramidal symptoms in patients with schizophrenia: associations with dopamine and serotonin receptor and transporter polymorphisms.","volume":"63","author":"Guzey","year":"2007","journal-title":"Eur J Clin Pharmacol"},{"key":"R8-2-20210128","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.pnpbp.2008.05.006","article-title":"Association between dopamine-related polymorphisms and plasma concentrations of prolactin during risperidone treatment in schizophrenic patients.","volume":"32","author":"Yasui-Furukori","year":"2008","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"R9-2-20210128","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.biopsych.2006.02.032","article-title":"Effects of short- and long-term risperidone treatment on prolactin levels in children with autism.","volume":"61","author":"Anderson","year":"2007","journal-title":"Biol Psychiatry"},{"key":"R10-2-20210128","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1192\/bjp.185.2.147","article-title":"Prolactin levels in antipsychotic treatment of patients with schizophrenia carrying the DRD2A1 allele.","volume":"185","author":"Young","year":"2004","journal-title":"Br J Psychiatry"},{"key":"R11-2-20210128","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/FPC.0b013e328329a60f","article-title":"Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents.","volume":"19","author":"Calarge","year":"2009","journal-title":"Pharmacogenet Genomics"},{"key":"R12-2-20210128","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1097\/FPC.0b013e3282f01aa3","article-title":"CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine.","volume":"17","author":"Aklillu","year":"2007","journal-title":"Pharmacogenet Genomics"},{"key":"R13-2-20210128","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1146\/annurev.med.52.1.503","article-title":"Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia.","volume":"52","author":"Kapur","year":"2001","journal-title":"Annu Rev Med"},{"key":"R14-2-20210128","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.neuropharm.2004.07.034","article-title":"Phenotypic analysis of dopamine receptor knockout mice; recent insights into the functional specificity of dopamine receptor subtypes.","volume":"47","author":"Holmes","year":"2004","journal-title":"Neuropharmacology"},{"key":"R15-2-20210128","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1517\/14622416.5.6.691","article-title":"Pharmacogenetics of dopamine receptors and response to antipsychotic drugs in schizophrenia-an update.","volume":"5","author":"Scharfetter","year":"2004","journal-title":"Pharmacogenomics"},{"key":"R16-2-20210128","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1006\/bbrc.1996.1296","article-title":"Proposed schizophrenia-related gene polymorphism: expression of the Ser9Gly mutant human dopamine D3 receptor with the Semliki Forest virus system.","volume":"225","author":"Lundstrom","year":"1996","journal-title":"Biochem Biophys Res Commun"},{"key":"R17-2-20210128","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/sj.mp.4000249","article-title":"Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients.","volume":"2","author":"Steen","year":"1997","journal-title":"Mol Psychiatry"},{"key":"R18-2-20210128","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/(SICI)1096-8628(20000403)96:2<187::AID-AJMG13>3.0.CO;2-8","article-title":"Association of dopamine D3-receptor gene variants with neuroleptic induced akathisia in schizophrenic patients: a generalization of Steen's study on DRD3 and tardive dyskinesia.","volume":"96","author":"Eichhammer","year":"2000","journal-title":"Am J Med Genet"},{"key":"R19-2-20210128","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0893-133X(02)00293-2","article-title":"Pharmacogenetics of tardive dyskinesia: combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism.","volume":"27","author":"Lerer","year":"2002","journal-title":"Neuropsychopharmacology"},{"key":"R20-2-20210128","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/01.jcp.0000150226.84371.76","article-title":"Dopamine D3 receptor Ser9Gly polymorphism and risperidone response.","volume":"25","author":"Lane","year":"2005","journal-title":"J Clin Psychopharmacol"},{"key":"R21-2-20210128","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1097\/JCP.0b013e3181ee84c7","article-title":"Lopez-Rodriguez, R, Roman, M, et al. Effects of CYP2D6 genotype on the pharmacokinetics, pharmacodynamics and safety of risperidone in healthy volunteers.","volume":"30","author":"Novalbos","year":"2010","journal-title":"J Clin Psychopharmacol"},{"key":"R22-2-20210128","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.2165\/00003495-200464200-00003","article-title":"Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management.","volume":"64","author":"Haddad","year":"2004","journal-title":"Drugs"},{"key":"R23-2-20210128","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1177\/0269881107078281","article-title":"Prevalence of hyperprolactinaemia in a naturalistic cohort of schizophrenia and bipolar outpatients during treatment with typical and atypical antipsychotics.","volume":"21","author":"Bushe","year":"2007","journal-title":"J Psychopharmacol"},{"key":"R24-2-20210128","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1089\/cap.2006.16.317","article-title":"The effect of long-term antipsychotic treatment on prolactin.","volume":"16","author":"Staller","year":"2006","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"R25-2-20210128","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3109\/10401230209147453","article-title":"The effects of atypical antipsychotics on serum prolactin levels.","volume":"14","author":"Hamner","year":"2002","journal-title":"Ann Clin Psychiatry"},{"key":"R27-2-20210128","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1111\/j.1440-1681.1992.tb00511.x","article-title":"A study of serum prolactin levels in schizophrenia: comparison of males and females.","volume":"19","author":"Kuruvilla","year":"1992","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"suppl 2","key":"R28-2-20210128","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0306-4530(02)00128-2","article-title":"Hyperprolactinemia in response to antipsychotic drugs: characterization across comparative clinical trials.","volume":"28","author":"Kinon","year":"2003","journal-title":"Psychoneuroendocrinology"},{"key":"R29-2-20210128","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1007\/s00406-004-0505-2","article-title":"Possible individual and gender differences in the small increases in plasma prolactin levels seen during clozapine treatment.","volume":"254","author":"de Leon","year":"2004","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"R30-2-20210128","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1600-0447.2006.00897.x","article-title":"Prolactin level during 5 years of risperidone treatment in patients with psychotic disorders.","volume":"115","author":"Eberhard","year":"2007","journal-title":"Acta Psychiatr Scand"},{"key":"R31-2-20210128","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s004060170053","article-title":"Association between TaqI A dopamine D2 receptor polymorphism and therapeutic response to bromperidol: a preliminary report.","volume":"251","author":"Suzuki","year":"2001","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"R32-2-20210128","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1002\/humu.20039","article-title":"Identification and characterization of ANKK1: a novel kinase gene closely linked to DRD2 on chromosome band 11q23.1.","volume":"23","author":"Neville","year":"2004","journal-title":"Hum Mutat"},{"key":"R33-2-20210128","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s12640-010-9219-6","article-title":"The ANKK1 protein associated with addictions has nuclear and cytoplasmic localization and shows a differential response of Ala239Thr to apomorphine.","volume":"20","author":"Garrido","year":"2011","journal-title":"Neurotox Res"},{"key":"R34-2-20210128","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0893-133X(98)00114-6","article-title":"Association of the MscI polymorphism of the dopamine D3 receptor gene with tardive dyskinesia in schizophrenia.","volume":"21","author":"Basile","year":"1999","journal-title":"Neuropsychopharmacology"},{"key":"R35-2-20210128","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1097\/00004714-199604000-00008","article-title":"ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. U.S. SEROQUEL Study Group.","volume":"16","author":"Borison","year":"1996","journal-title":"J Clin Psychopharmacol"},{"key":"R36-2-20210128","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/hup.811","article-title":"Prolactin elevation of the antipsychotic risperidone is predominantly related to its 9-hydroxy metabolite.","volume":"21","author":"Melkersson","year":"2006","journal-title":"Hum Psychopharmacol"},{"key":"R37-2-20210128","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1176\/appi.ajp.162.5.1010","article-title":"Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels.","volume":"162","author":"Knegtering","year":"2005","journal-title":"Am J Psychiatry"},{"key":"R38-2-20210128","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1177\/0269881107077357","article-title":"Serum prolactin levels, plasma risperidone levels, polymorphism of cytochrome P450 2D6 and clinical response in patients with schizophrenia.","volume":"21","author":"Wang","year":"2007","journal-title":"J Psychopharmacol"},{"key":"R39-2-20210128","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/j.pnpbp.2007.04.021","article-title":"Association between major multidrug resistance 1 (MDR1) gene polymorphisms and plasma concentration of prolactin during risperidone treatment in schizophrenic patients.","volume":"31","author":"Yasui-Furukori","year":"2007","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"}],"container-title":["Journal of Clinical Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00004714-201110000-00002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,10]],"date-time":"2021-04-10T06:17:07Z","timestamp":1618035427000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00004714-201110000-00002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/jcp.0b013e31822cfff2","relation":{},"ISSN":["0271-0749"],"issn-type":[{"value":"0271-0749","type":"print"}],"subject":[],"published":{"date-parts":[[2011,10]]}}}